SNY - Sanofi

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Regeneron posts Q4 beat even as Eylea, COVID-19 sales dip
• Sanofi proposes annual dividend of €3.76
• Sanofi incurs loss in Q4 amid generic competition, currency woes
• Sanofi Non-GAAP EPS of €1.66, revenue of €10.92B; initiates FY24 outlook
• Watch GSK amid evidence hearing on Zantac litigation
• Sanofi to acquire Inhibrx rare disease asset in $2.2B deal
• Sanofi on track to snap its six-day win streak
• FDA evaluating reports of GLP-1 drugs and negative side effects
• Florida wins FDA nod for mass drug imports from Canada (update)
• Masking returns to some U.S. hospitals amid rising COVID, flu cases
• Scribe Therapeutics expands collaboration with Sanofi
• AstraZeneca, Sanofi RSV infant shot authorized in China
• Drugmakers reportedly planning to raise prices on 500+ drugs in January
• FDA’s new drug approvals for 2023 rise 51% from last year
• Sanofi ending development of tusamitamab ravtansine after study failure
• Innate Pharma jumps 15% on licensing natural killer cell engager with Sanofi
• EU regulators issue positive opinion on Sanofi sleeping sickness drug
• Biden administration secures 230K more RSV injections for infants
• Sanofi pulls the plug on licensing deal with Maze Therapeutics after FTC challenge
• Vanda stock jumps on $100M license deal for MS drug from J&J unit